# Viridian Therapeutics share price today (Viridian Therapeutics, Inc., VRDN)

> Viridian Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VRDN · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/vrdn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $28.55 (+4.0% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: −₹0.1 B (one-off item, see below)
- ROE: −39%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Viridian Therapeutics share price today? Viridian Therapeutics, Inc.'s share price was $28.55 at the close on 5 November 2026. It has been stalling near its high for 3 weeks. That is 31.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $13 and $33, and at that close it sat 76% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row. Over the last 9.7 years the share price moved −84% while the S&P 500 moved +212%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Viridian Therapeutics pay? Viridian Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Viridian Therapeutics on? Viridian Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Viridian Therapeutics profitable? Viridian Therapeutics, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.3 B. That loss is 39,727.1% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 B. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −44,460.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Viridian Therapeutics make, and is it growing? Viridian Therapeutics, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, +278.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 121.1% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.1 B. Recent pace: the last four quarters grew +152.6% on average, against 121.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +23,220.3%, against +1,471.5% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Viridian Therapeutics keep? Viridian Therapeutics, Inc. has almost no sales yet: FY25 revenue was ₹0.1 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Viridian Therapeutics' profit turning into cash? Viridian Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.3 B of cash, against −₹0.3 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.3 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Viridian Therapeutics' cash go? Viridian Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Viridian Therapeutics' P/E ratio, and how does it compare with its own history? Viridian Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Viridian Therapeutics business getting better or worse? Viridian Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Viridian Therapeutics earn on its capital? Viridian Therapeutics, Inc. earned a ROE of −39% in FY25. That is up from a low of −42% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −43%, a number that says nothing useful about the business. ## Does Viridian Therapeutics have too much debt? Viridian Therapeutics, Inc. has total debt of ₹0.2 B against shareholder equity of ₹0.7 B as of Jun 2026, so its debt is 0.37× its equity. Year by year, that ratio went from 0.00 in FY21 to 0.07 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Viridian Therapeutics shareholding pattern? 17.9% of Viridian Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Viridian Therapeutics from balance-sheet trouble? For Viridian Therapeutics, Inc., the Z-score is 0.55. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.55 is inside the danger zone, so the balance sheet is a real risk. ## How does Viridian Therapeutics rank in its industry? There is no score against its industry: Viridian Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Viridian Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Viridian Therapeutics in size? Viridian Therapeutics is the 58th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Arcutis Biotherapeutics, Inc., Telix Pharmaceuticals and Tarsus Pharmaceuticals, Inc. Just below it: Denali Therapeutics Inc., IDEAYA Biosciences, Inc. and ADMA Biologics, Inc. ### Biotechnology companies close in size

1. [Arcutis Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/arqt) $3.4 billion
2. [Telix Pharmaceuticals Limited](https://www.sectoralpha.in/us/stocks/tlx) $3.3 billion
3. [Tarsus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/tars) $3.3 billion
4. Viridian Therapeutics, Inc. $3.2 billion
5. [Denali Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/dnli) $3.2 billion
6. [IDEAYA Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/idya) $3 billion
7. [ADMA Biologics, Inc.](https://www.sectoralpha.in/us/stocks/adma) $2.9 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Seaboard Corporation](https://www.sectoralpha.in/us/stocks/seb) $3.3 billion · Conglomerates
2. [Kenon Holdings Ltd.](https://www.sectoralpha.in/us/stocks/ken) $3.3 billion · Utilities - Independent Power Producers
3. Viridian Therapeutics, Inc. $3.3 billion
4. [Stride, Inc.](https://www.sectoralpha.in/us/stocks/lrn) $3.3 billion · Education & Training Services
5. [Artisan Partners Asset Management Inc.](https://www.sectoralpha.in/us/stocks/apam) $3.3 billion · Asset Management

## What else do people ask about Viridian Therapeutics? ### What were Viridian Therapeutics's latest quarterly results? Viridian Therapeutics, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.1 B for the Jun 2026 quarter. The operating margin was −44,460.6%, 97,895.4 percentage points higher than a year earlier (as of 5 November 2026). ### What is Viridian Therapeutics's market cap? Viridian Therapeutics, Inc.'s market capitalisation is $3.2 B at a stock price of $28.55. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Viridian Therapeutics performing? Viridian Therapeutics, Inc.'s share price has been stalling near its high for 3 weeks. Over the past 13 weeks it has done better than the S&P 500, for 4 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Viridian Therapeutics's stock price go up? This page does not forecast Viridian Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $28.55, and it has been stalling near its high for 3 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Viridian Therapeutics have too much debt? Viridian Therapeutics, Inc. has a moderate amount of debt: its debt is 0.42× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### What could break the Viridian Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Viridian Therapeutics a stock worth studying right now? What the numbers show: Viridian Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.